Convalescent Plasma Infusion in Italian Hospitalized Patients with Severe COVID 19 Pneumonia: Evaluation of Late Mortality Associated Factors

Gianluca Gessoni *

Transfusion Medicine Department, ULSS 3 Serenissima, Italy.

Giovanni Roveroni

Transfusion Medicine Department, ULSS 3 Serenissima, Italy.

Lauretta Moro

Transfusion Medicine Department, ULSS 3 Serenissima, Italy.

Michela Pivetta

Transfusion Medicine Department, ULSS 3 Serenissima, Italy.

Michele Tessarin

Department of Health Management, University of Padua, Italy.

Domenico Bagnara

Department of Management Control, ULSS 3 Serenissima, Italy.

Sara Valverde

Department of Clinical Pathology, ULSS 3 Serenissima, Italy.

Rossi Carla

Transfusion Medicine Department, ULSS 3 Serenissima, Italy.

Coluccia Enza

Transfusion Medicine Department, ULSS 3 Serenissima, Italy.

Collodel Luca

Transfusion Medicine Department, ULSS 3 Serenissima, Italy.

Roberto Valle

Cardiology and Intensive Coronary Unit, ULSS 3 Serenissima, Italy.

Giovanni Carretta

Department of Health Management, ULSS 3 Serenissima, Italy.

*Author to whom correspondence should be addressed.


Background: This was a single center prospective study about factors related with mortality in hospitalized patients with severe COVID-19 pneumonia treated with convalescent plasma (CCP) infusion in Venice Prefecture.

Methods: In this study were enrolled all the (376) consecutive hospitalized patients with severe COVID-19 pneumonia treated with CCP observed from 30/04/2020 to 31/10/2021.  At hospital admission, in order to evaluate correlation with prognosis, study recorded demographic data, clinical data, presence of co morbidities, Rx findings, laboratory results.  The endpoint was mortality at 30 days.

Results: Using multivariate analysis, considering demographic data and co morbidities four variables emerged as significant independent predictors of 30-day mortality:  age>70 years, tobacco smoke, obesity (BMI>30), Diabetes. Considering Patients’ clinical characteristics at hospital admission two variables emerged as significant independent predictors of 30-day mortality in this cohort of hospitalized patients with severe COVID-19 Pneumonia: PaO2/FiO2 ratio under 200 and lungs imaging with a score >3.

Discussion: Late mortality was investigated in a series of consecutive, hospitalized, patients with severe COVID-19. We therefore believe that any influence linked to the level of expertise of the clinical staff and available technology was minimal. Furthermore, we also tried to reduce, as much as possible, the variables related CCP infusion using plasma with a neutralizing antibody titer> 80 and a standardized dose: a 200 mL unit per day for three consecutive days. Moreover, using both a univariate and multivariate analytical approach, numerous demographic variables were considered, relating to comorbidities, all clinical characteristics, to laboratory data; correlating them with mortality at 30 days.

Keywords: COVID-19, convalescent plasma, mortality, pneumonia, risk factors

How to Cite

Gessoni, G., Roveroni, G., Moro , L., Pivetta , M., Tessarin, M., Bagnara , D., Valverde, S., Carla, R., Enza, C., Luca, C., Valle, R., & Carretta , G. (2023). Convalescent Plasma Infusion in Italian Hospitalized Patients with Severe COVID 19 Pneumonia: Evaluation of Late Mortality Associated Factors. International Blood Research & Reviews, 14(2), 12–33.


Download data is not yet available.


Abenavoli L, Cinaglia P, Luzza F, Gentile I, Boccuto L. Epidemiology of Coronavirus Disease Outbreak: The Italian Trends. Rev Recent Clin Trials 2020;15:87-92.

Spuri M, Cataldo C, Del Manso M, Fabiani M, Petrone D, Boros S, Sacco C, Urdiales AM, Masella R, Bressi M, Bella A. Epidemiological characteristics of COVID-19 cases in Italy: An analysis from a sex/gender perspective. Italian Journal of Gender-Specific Medicine. 2022;8(1):3-9.

Rome BN, Avorn J. Drug evaluation during the Covid-19 pandemic. N Engl J Med 2020;382:2282-4.

Xie M, Chen Q. Insight into 2019 novel coronavirus - An updated interim review and lessons from SARS-CoV and MERS-CoV. Int J Infect Dis 2020;94:119-24.

van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S, et al. Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. N Engl J Med 2016;74:33-42.

Peeri NC, Shrestha N, Rahman MS, Zaki R, Tan Z, Bibi S, et al. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? Int J Epidemiol. 2020;49;717- 26.

Salazar MR, Gonzalez SE, Regairaz L, Ferrando NS, González Martínez VV, et al. Effect of convalescent plasma on mortality in patients with COVID-19 pneumonia. medRxiv preprint. October 2020.

Available: 10.1101/2020.10.08.20202606.

Horby P, Estcourt L, Peto L, on behalf of the Recovery Collaborative Group. Convalescent plasma in patients admitted to hostital with COVID-19 (RECOVERY): A randomized controlled, open label, platform trial. Lancet. 2021;397:2049-59.

Simonovich VA, Burgos Pratx LD, Scibona P, Maruto MV, Vallone MG, Vazquez C, et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med 2021;384:619–29.

Ferreira-Barreira D, Aduberio-Lourenco R, Calisto R, Moreira-Consalves D, Santos LL, Videira PA. Assessment of the Safety and Therapeutic Benefits of Convalescent Plasma in COVID-19 Treatment: A Systematic Review and Meta-Analysis. Front Med (Lausanne) 2021; DOI: 10.3389/fmed.2021.660688.

Ying W, Pengfei H, Rulin D, Xin L, Yuan S, Zhang Y, et al. Convalescent plasma may be a possible treatment for COVID-19: A systematic review. Int Immunopharmacol; 2020. DOI: 10.1016/j.intimp.2020.107262. Epub Dec 5

Begin P, Callum J, Jamula E, Cook R, Heddle NM, Tinmouth A, et al. Convalescent plasma for hospitalized patients with COVID-19: An open-label, randomized controlled trial. Nature Medicine 2021;27:2012-24.

Casadevall A, Dragotakes Q, Johnson PW, Senefeld JW, Klassen SA, Wright RS, et al. Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality. Elife 2021;10:e69866.

Luo Wenjing, Feng Yuanzheng, Jun-Ying Li, Tang LV, Yu H. Safety and efficacy of convalescent plasma therapy in severely and critically ill patients with COVID-19: a systematic review with meta-analysis. Aging 2021;13:1498-1509.

Ranieri M, Rubenfeld G, Thompson T, Ferguson ND, Caldwell E, Fan E, et al. Acute respiratory distress syndrome: The Berlin definition. JAMA. 2012;307:2526-33.

Lambden S, Laterre PF, Levy MM, Francois B. The SOFA score—development, utility and challenges of accurate assessment in clinical trials. Critical Care. 2019;23:374-82.

DM 02/11/2015 Disposizioni relative ai requisiti di qualita' e sicurezza del sangue e degli emocomponenti. GU Serie Generale n.300 del 28-12-2015 – (Suppl. Ordinario n. 69)

Istituto Superiore di Sanità. Centro Nazionale Sangue; 2021. Available: %2028-12-2015_SO_069.pdf Accessed December 27.

Gessoni G, Moro L, Orfano M, Pivetta M, Dittadi R, Pacenti M, et al. Valutazione degli anticorpi anti SARS-CoV-2 nell’ambito di un progetto di costituzione di una banca del plasma iperimmune. Biochimica Clinica; 2021.

DOI 10.191866/BC_2021_008.

Franchini M, Marano G, Velati C, Pati I, Pupella S, Liumbruno GM. Operational protocol for donation of anti-COVID-19 convalescent plasma in Italy. Vox Sang; 2020. DOI: 10.1111/vox.12940.

De Silvestro G, Marson P, La Raja M, Cattelan AM, Guarnieri G, Monticelli J, el al. Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) Registry. Europ J Int Med 2021

Henry BM, de Oliveira MHS, Benoit S, et al. Hematologic, biochemical and immune biomarker abnormali¬ties associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): A meta-analysis. Clin Chem Lab Med. 2020;58; 1021–8.

Li LQ, Huang T, Wang YQ, et al. COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol 2020;92;577–83.

Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46;846–8.

Hong W, Chen Q, Qian S, Basharat Z, Zimmer V, Wang Y, et al. Critically Ill vs. Non-Critically Ill Patients With COVID-19 Pneumonia: Clinical Features, Laboratory Findings, and Prediction. Front. Cell. Infect. Microbiol. 11:550456.

DOI: 10.3389/fcimb.2021.550456

Franchini M, Glingani M, De Donno G, Lucchini G, Beccaria M, Amato M et al. Convalescent plasma for hospitalized COVID-19 patients: A single-center experience. Life; 2022.

Palaiodimos L, Kokkinidis DG, Li W, et al. Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID- 19 in the Bronx, New York. Metabolism. 2020;108;154262.

Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani M et al. Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy. JAMA. 2020; 180:1-11.

Grasselli G, Zangrillo A, Zanella A, et al. COVID-19 lombardy ICU network. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323:1574-1581.

Xie J, Covassin N, Fan Z, et al. Association between hypoxemia and mortality in patients with COVID-19. Mayo Clin Proc 2020;95;1138–47.

Mullen B. COVID-19 clinical guidance for the cardiovascular care team. American College of Cardiology; 2022.

Available: Accessed October 25,

Chung M, Bernheim A, Mei X, et al. CT imaging features of 2019 novel coronavirus (2019-nCoV). Radiology. 2020;295:202–207.

Spagnolo P, Cozzi A, Foà RA, et al. CT-derived pulmonary vascular metrics and clinical outcome in COVID-19 patients. Quant Imaging Med Surg. 2020;10:1325–1333.

Borghesi A, Zigliani A, Golemi S, et al. Chest X-ray severity index as a predictor of in-hospital mortality in coronavirus disease 2019: a study of 302 patients from Italy. Int J Infect Dis. 2020;96:291–293.

Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): A meta-analysis. Clin Chem Lab Med. 2020;58: 1021–1028.

Shang W, Dong J, Ren Y, et al. The value of clinical parameters in predicting the severity of COVID-19. J Med Virol. 2020 DOI 10.1002/jmv.26031.

Franks CE, Scott MG, Farnsworth CW. Elevated cardiac troponin I is associated with poor outcomes in COVID-19 patients at an academic medical center in Midwestern USA. J Appl Lab Med; 2020. DOI:10.1093/jalm/jfaa092.

Vrsalovic M, Vrsalovic PA. Cardiac troponins predict mortality in patients with COVID-19: A meta-analysis of adjusted risk estimates. J Infect; 2020. DOI:10.1016/j.jinf.2020.05.022.

Shi S, Qin M, Cai Y, et al. Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019. Eur Heart J. 2020;41(22):2070–2079. DOI:10.1093/eurheartj/ehaa408. [PubMed: 32391877]

Toraih EA, Elshazli RM, Hussein MH, et al. Association of cardiac biomarkers and comorbidities with increased mortality, severity, and cardiac injury in COVID-19 patients: a meta-regression and Decision tree analysis. J Med Virol; 2020. DOI:10.1002/jmv.26166.

Tan C, Huang Y, Shi F, et al. C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early. J Med Virol. 2020;92 (7):856–862. DOI:10.1002/jmv.25871. [PubMed: 32281668]

Poggiali E, Zaino D, Immovilli P, et al. Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients. Clin Chim Acta. 2020;509:135–138. DOI:10.1016/j.cca.2020.06.012. [PubMed: 32531257]

Zhang L, Yan X, Fan Q, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost. 2020;18(6):1324–1329. DOI:10.1111/jth.14859. [PubMed: 32306492]

Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020;7(6):e438–e440. DOI:10.1016/S2352-3026(20)30145-9. [PubMed: 32407672]

Yang Z, Hu Q, Huang F, Xiong S, Sun Y. The prognostic value of the SOFA score in patients with COVID-19: a retrospective, observational study. Medicine 2021;100:32(e26900).